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Abstract
Background: Implantable cardioverter defibrillator (ICD) is an effective treatment for secondary prevention of ventricular
tachycardia/ventricular fibrillation (VT/VF). Left ventricular (LV) remodeling may develop before ICD implant and over time.
However, it remains unclear how LV remodeling affects subsequent risk for recurrence VT/VF in ICD recipients under
optimal medical therapy.
Methods: From May of 2004 to June of 2015, 144 patients received ICD implantation for secondary prevention were
enrolled in this study. All information interrogated from ICD devices during follow-up or ICD therapy history (anti-
tachycardia pacing and shock therapy) were reviewed and validated the occurrences of VT/VF.
Results: At a mean follow-up of 1110.5 ± 860.6 days, 53 patients (36.8%) had recurrence of VT/VF episodes and 91
patients had no recurrence of VT/VF episode after ICD implant. Left ventricular end-diastolic volume (LVEDV) > 163.5 mL
had significant predictive value for VT/VF recurrence (area under the curve: 0.602, p = 0.041). Moreover, the percentage of
patients with LVEDV >163.5 mL was significantly higher in patients with recurrent VT/VF than patients without recurrent
VT/VF (62.3 vs 40.0%, p = 0.010). Left ventricular ejection fraction≤ 30% (p = 0.031), LVEDV > 163.5 mL (p = 0.012) and QRS
width > 125 msec (p= 0.049) were significant predictors for VT/VF recurrence by univariate Cox regression analysis.
However, only LVEDV > 163.5 mL (hazard ratio: 2.549, 95% confidence interval: 1.249 ~ 5.201, p = 0.010) and QRS width
> 125 msec (hazard ratio: 2.173, 95% confidence interval: 1.030 ~ 4.586, p = 0.042) were independent predictors for
recurrence of VT/VF after multivariable adjustment.
Conclusion: LV remodeling and QRS width > 125 msec were independent predictors for VT/VF recurrence in secondary
prevention ICD recipients under optimal medical therapy, independent of LV ejection fraction.
Keywords: Implantable cardioverter defibrillator, Ventricular remodeling, Ventricular tachycardia
Background
Implantable cardioverter defibrillator (ICD) has been
confirmed to be an effective treatment for selected pa-
tients who are survivors of sustained ventricular tachy-
cardia/ventricular fibrillation (VT/VF) unrelated to
transient correctable causes or are at risk of sudden
cardiac death [1]. Several studies have consistently con-
firmed the preponderance of ICD therapy over anti-
arrhythmic therapy in terms of primary or secondary
prevention of sudden cardiac death and mortality in pa-
tients with heart failure and reduced left ventricular (LV)
function [2–7]. However, ICD therapy is an expensive
therapy and is reimbursed only for secondary prevention
in many developing countries. Additionally, some ICD
recipients for primary or secondary prevention may
never experience recurrence of VT/VF and shock ther-
apy during follow-up under optimal medical therapy,
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including ß–blockers and renin-angiotensin-aldosterone
antagonists, and modification of risk factors. Therefore,
clinical predictors for recurrent VT/VF as the guidance
for ICD replacement are requisite for limited healthcare
resources in many developing countries. The majority of
studies of clinical predictors for recurrent VT/VF en-
rolled both primary and secondary prevention ICD re-
cipients. Klein et al. reported that LV ejection fraction <
40%, permanent atrial fibrillation and QRS duration >
150 msec are independent predictors for VT/VF recur-
rence in ICD recipients for primary and secondary pre-
vention [8]. However, there are limited reports regarding
clinical predictors for recurrent VT/VF in patients re-
ceived ICD only for secondary prevention. Interestingly,
Freedberg et al. reported no predictor for subsequent
ICD therapy in patients receiving ICD for symptomatic
VT or cardiac arrest [9].
Left ventricular remodeling associated with underling
heart disease may develop before ICD implant and over
time after implant. Moreover, ß–blockers and renin-
angiotensin-aldosterone antagonists have been shown to
inhibit or reverse LV remodeling rather than changes in
LV ejection fraction [10]. However, it remains unclear how
LV remodeling affects subsequent risk for recurrence VT/
VF in ICD recipients for secondary prevention. Accord-
ingly, we conducted this study to investigate the role of
LV remodeling as a predictor for the recurrence of VT/VF




From May of 2004 to June of 2015, 144 patients received
ICD implantation for secondary prevention were enrolled
in this study. All information interrogated from ICD de-
vices during follow-up or ICD therapy history (anti-tachy-
cardia pacing and shock therapy) were reviewed and
validated the occurrences of VT/VF and ICD therapy.
Ninety-one patients who did not have any VT/VF episode
or ICD therapy during follow-up after ICD implant were
defined as the “no recurrent VT/VF group”, whereas 53
patients who had experienced VT/VF episodes and appro-
priate ICD therapies during follow-up after implant were
defined as the “recurrent VT/VF group”.
Definitions
Left ventricular diastolic dysfunction was categorized into
3 stages: stage I (impaired relaxation), stage II (pseudonor-
malization) and stage III (restrictive filling pattern) ac-
cording to the echocardiographic patterns of mitral inflow
velocity, mitral Doppler tissue imaging of mitral annular
motion and pulmonary venous flow. The LV end-diastolic
volume (LVEDV) and LV end-systolic volume (LVESV)
were quantified by M-mode echocardiography and were
corrected by two-dimensional guided biplanar Simpson’s
method of discs for measurement [11, 12].
Atrial fibrillation was defined as paroxysmal if atrial
fibrillation episode lasting for 7 days or less, persistent if
continuous atrial fibrillation episode lasting for more
than 7 days, and longstanding persistent if continuous
atrial fibrillation episode lasting for more than 1 year.
Study endpoints
The primary study endpoints were the recurrence of
VT/VF and ICD therapy. The secondary endpoints were
cardiovascular death (death related to heart failure and
cardiac arrhythmia) and all-cause mortality (including
sepsis, hepatic failure and brain hemorrhage).
Statistical analysis
Data are presented as mean ± SD or percentage. The clin-
ical characteristics (general demographics, underling heart
diseases, comorbidities, functional class of heart failure,
QRS duration, medications, LVEDV, LVESV, LV function,
VT/VF detection zone and VT ablation) between the study
groups were compared using t-test for continuous variables
or chi-square test for categorical variables. Receiver operat-
ing characteristic curve analysis was used to calculate the
area under the curve for the optimal volume of LVEDV,
LVESV and QRS width in predicting the recurrence of VT/
VF. Univariate and multivariate Cox regression analyses
were performed to identify the significant predictors for the
recurrence of VT/VF after implant. Each independent vari-
able was based on previous studies and conventional risk
factors, and was expressed as a hazard ratio with 95% confi-
dence interval. The Kaplan-Meier method and log-rank test
were used to compare the event-free survival of the recur-
rence of VT/VF during follow-up. Statistical analysis was
performed using statistical software (SPSS for Windows,
version 22). A two-sided p value of < 0.05 was considered
statistically significant.
Results
Baseline characteristics of study patients
At a mean follow-up of 1110.5 ± 860.6 days, 53 patients
(36.8%) had recurrence of VT/VF episodes and 91 patients
had no recurrence of any VT/VF episode after ICD im-
plant (Fig. 1). Table 1 lists the clinical characteristics of
the study group. In this study, 71.5% of patients received
renin-angiotensin-aldosterone antagonists and 60.4% of
patients received ß–blocker therapy. The average age of
patients in recurrent VT/VF group was 60 ± 13 years, and
77.4% of the patients were male. The average age of pa-
tients in no recurrent VT/VF group was 63 ± 14 years,
and 80.2% of the patients were male. Patients with coron-
ary artery disease in recurrent VT/VF group had higher
prevalence of revascularization with coronary artery by-
pass graft surgery than patients with coronary artery
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disease in no recurrent VT/VF group. There was no
significant difference in age, gender, body mass index,
underling heart diseases, prevalence of comorbidities and
atrial fibrillation, frequency of medications related to
comorbidities and anti-arrhythmics, the average dosage of
ß-blocker and anti-arrhythmics, QRS duration, the per-
centages of left bundle branch block and ventricular-
dependent pacing, stage of LV diastolic dysfunction and
heart failure status between the two groups. There was no
significant difference in the prevalence of unstable VT (p
= 0.590) and VT ablation plus medications (anti-arrhyth-
mics and ß-blocker) (p = 0.358) between the two groups.
Seventy nine patients received single chamber ICD and 65
patients received dual chamber ICD. There was no signifi-
cant difference in the ICD type and the percentage of car-
diac resynchronization therapy defibrillator recipients
between the two groups. The lowest VT- and VF-
detection rates were similar between two groups. Fifteen
patients (10.4%) received catheter ablation and modifica-
tion of arrhythmic substrates, including 6 patients (6.6%)
in no recurrent VT/VF group, and 9 patients (17.0%) in
recurrent VT/VF group (p = 0.087) (Table 1).
Determinants of recurrence of VT/VF during follow-up
Although there was no significant difference in LV ejec-
tion fraction between the two groups, LVEDV and
LVESV were larger in patients with recurrent VT/VF
than patients without recurrent VT/VF (Table 1). Re-
ceiver operating characteristic curve analysis was used to
calculate the area under the curve for the optimal vol-
ume of LVEDV and LVESV in predicting the recurrence
of VT/VF. Only LVEDV > 163.5 mL had significant pre-
dictive value for the recurrence of VT/VF (area under
the curve: 0.602, p = 0.041). Moreover, the percentage of
patients with LVEDV >163.5 mL was significantly higher
in patients with recurrent VT/VF than patients without
recurrent VT/VF (p = 0.010). Receiver operating charac-
teristic curve analysis was also used to calculate the area
under the curve for the optimal duration of QRS width
in predicting the recurrence of VT/VF. QRS width over
125 msec had the best predictive value, although it did
not reach statistical significance (area under the curve:
0.563, p = 0.209). Eighty-six patients (59.7%) had follow-
up echocardiograms at a median follow-up period of
939.5 days. Notably, LVEDV at follow-up were signifi-
cantly larger in patients with recurrent VT/VF than pa-
tients without recurrent VT/VF (191.00 ± 76.61 vs.
158.15 ± 57.82 mL, p = 0.028). Moreover, there was a
trend, but not statistically significant that patients with
no recurrent VT/VF were more likely to have reverse re-
modeling of LVEDV more prominently (−21.73 ± 54.49
vs. -0.74 ± 55.72 mL, p = 0.083) and more frequently
(58.3% vs. 44.7%, p = 0.266) compared with patients with
recurrent VT/VF (Fig. 2). The LV ejection fraction at
follow-up remained similar between patients with recur-
rent VT/VF and patients without recurrent VT/VF
(47.2 ± 16.3 vs. 46.7 ± 16.2%, p = 0.885).
By univariate Cox regression analyses, LV ejection frac-
tion ≤ 30% (p = 0.031), larger LVEDV (p = 0.028), LVEDV>
163.5 mL (p = 0.012), and larger LVESV (p = 0.025) were
significant predictors for VT/VF recurrence during
follow-up (Table 2). QRS width > 125 msec was also a sig-
nificant predictor for VT/VF recurrence during follow-up
(p = 0.049). There was a trend, but not statistically signifi-
cant that anti-arrhythmics had a protective role for VT/
VF recurrence (hazard ratio: 0.611, 95% confidence inter-
val: 0.298 ~ 1.252, p = 0.178) (Table 2). However, only
LVEDV > 163.5 mL (hazard ratio: 2.549, 95% confidence
interval: 1.249 ~ 5.201, p = 0.010) and QRS width >
125 msec (hazard ratio: 2.173, 95% confidence interval:
1.030 ~ 4.586, p = 0.042) were independent predictors for
recurrence of VT/VF during follow-up after multivariate
adjustment (Table 2) (Fig. 3).
Cardiovascular death and all-cause mortality during
follow-up
The average follow-up periods in the no VT/VF recurrence
group and the recurrent VT/VF group were 1019.5 ±
791.4 days and 1266.7 ± 1028.5 days, respectively (p =
0.108). The 1-year cardiovascular mortality was significant
higher in the recurrent VT/VF group than the no recur-
rence VT/VF group (9.4% vs. 1.1%, p = 0.028) (Table 1).
However, there was no significant difference in the 1-year
all-cause mortality between the two groups (9.4% vs. 5.5%,
p = 0.499).
Discussion
This study identifies and reports 36.8% of ICD recipients
for secondary prevention having recurrent VT/VF at a
mean follow-up of 1110.5 ± 860.6 days. LVEDV > 163.5 mL
Fig. 1 Kaplan-Meier plot proportion of patients free of recurrent
ventricular tachycardia/ventricular fibrillation (VT/VF) events after
implant in the study cohort
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Age (year) 63 ± 14 60 ± 13 0.166
Male gender 73 (80.2) 41 (77.4) 0.419
BMI 25.5 ± 4.7 25.1 ± 3.8 0.686
Heart disease
Congenital heart 4 (4.4) 0 (0) 0.297
CAD 51 (56.0) 29 (54.7) 0.979
Treatment in CAD patients 0.020
CABG 5 (9.8) 10 (34.5)
PCI 41 (80.4) 18 (62.1)
Medical treatment 5 (9.8) 1 (3.4)
DCM 16 (17.6) 11 (20.8) 0.397
HOCM 4 (4.4) 2 (1.9) 0.391
Idiopathic VF 8 (8.8) 3 (5.7) 0.370
Brugada syndrome 3 (3.3) 3 (5.7) 0.388
Long QT syndrome 4 (4.4) 3 (3.8) 0.391
Valvular heart disease 8 (8.8) 8 (15.1) 0.187
Comorbidity
Hypertension 52 (57.1) 26 (49.1) 0.222
Diabetes 24 (26.4) 20 (37.7) 0.108
Prior stroke 10 (11.0) 7 (13.2) 0.441
Hyperlipidemia 28 (30.8) 14 (26.4) 0.360
ESRD 6 (6.6) 5 (9.4) 0.377
Atrial fibrillation (%) 0.634
No 67 (73.6) 40 (75.5)
Paroxysmal 17 (18.7) 11 (20.8)
Persistent 7 (7.7) 2 (3.8)
Heart failure 0.865
Without heart failure 29 (31.9) 16 (30.2)
NYHA functional class I 16 (17.6) 11 (20.8)
NYHA functional class II 27 (29.7) 13 (24.5)
NYHA functional class III 14 (15.4) 8 (15.1)
NYHA functional class IV 5 (5.5) 5 (9.4)
Diastolic function (%) 0.322
Normal 11 (12.9) 11 (22.9)
Stage I 40 (47.1) 24 (50.0)
Stage II 14 (31.8) 8 (22.9)
Stage III 5 (8.2) 5 (4.2)
QRS length (msec) 115.3 ± 30.7 121.8 ± 32.3 0.231
LBBB 2 (2.2) 4 (7.5) 0.121
Medications
ACEI/ARB 63 (69.2) 32 (60.4) 0.184
ß-blocker 59 (64.8) 28 (52.8) 0.107
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Table 1 Baseline characteristics of study patients (Continued)
Bisoprolol (the average dose) (mg) 3.5 ± 2.2 3.2 ± 1.5 0.530
Carvedilol (the average dose) (mg) 17.2 ± 10.0 9.1 ± 13.1 0.651
Diuretic 30 (33.0) 15 (28.3) 0.348
Statin 29 (31.9) 20 (37.7) 0.473
Spironolactone 11 (12.1) 11 (20.8) 0.125
Anti-platelet agent 54 (59.3) 29 (54.7) 0.604
Warfarin 12 (13.2) 9 (17.0) 0.626
NOAC 3 (3.3) 0 (0) 0.297
Anti-arrhythmic medications
Amiodarone 62 (68.1) 33 (62.3) 0.295
The average dose (mg) 196.8 ± 85.4 214.3 ± 103.3 0.371
Dronedarone 2 (2.2) 0 (0) 0.532
The average dose (mg) 800
Quinidine 2 (2.2) 0 (0) 0.532
The average dose (mg) 600
Mexiletine 2 (2.2) 0 (0) 0.532
The average dose (mg) 300
Sotalol 1 (1.1) 0 (0) 1.000
The average dose (mg) 160
CRT-D 1 (1.1) 3 (5.7) 0.108
ICD chamber 0.731
Single 51 (56.0) 28 (52.8)
Dual 40 (44.0) 25 (47.2)
Ventricular-dependent pacing 4 (4.4) 1 (1.9) 0.428
Hemodynamic condition 0.590
Stable 60 (65.9) 32 (60.4)
Unstable 31 (34.1) 21 (39.6)
Lowest VT-detection zone (bpm) 165.9 ± 13.2 165.4 ± 10.5 0.865
Lowest VF-detection zone (bpm) 209.2 ± 13.5 208.2 ± 15.8 0.773
Post VT ablation (%) 6 (6.6) 9 (17.0) 0.087
Success 3 (50) 3 (33.3) 0.518
Failure 3 (50) 6 (66.7)
Combination of VT ablation plus medications (anti-arrhythmics and ß-blocker) 6 (6.6) 6 (11.3) 0.358
LV systolic function
LVEF (%) 49.5 ± 16.7 44.6 ± 18.5 0.105
LVEDV (mL) 162.0 ± 68.1 186.4 ± 84.5 0.060
LVEDV > 163.5 mL 36 (40.0) 33 (62.3) 0.010
LVESV (mL) 88.2 ± 61.3 111.4 ± 81.6 0.055
1-year CV mortality 1 (1.1) 5 (9.4) 0.028
1-year all-cause mortality 5 (5.5) 5 (9.4) 0.499
Follow-up time (days) 1019.5 ± 791.4 1266.7 ± 1028.5 0.108
Data are expressed as mean ± SD or as number (percentage)
*Abbreviations: VT ventricular tachycardia, VF ventricular fibrillation, BMI body mass index, CAD coronary artery disease, CABG coronary artery bypass graft surgery,
PCI percutaneous coronary intervention, DCM dilated cardiomyopathy, HOCM hypertrophic obstructive cardiomyopathy, RVOT right ventricular outflow tract, ESRD
end stage renal disease, LVEF left ventricular ejection fraction, LVEDV left ventricular end diastolic volume, LVESV left ventricular end systolic volume, NYHA New
York Heart Association, LBBB left bundle branch block, NOAC non-vitamin K oral anticoagulants, CRT-D, cardiac resynchronization therapy-defibrillator, ACEI
angiotensin-converting-enzyme inhibitor, ARB angiotensin receptor blocker, CV cardiovascular
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and QRS width > 125 msec were independent predictors
for recurrence of VT/VF during follow-up after multivari-
able adjustment.
In the multicentre COMFORT trial, Zaman et al. re-
ported that secondary prevention ICD recipients had
more recurrent VT/VF than primary prevention ICD re-
cipients (37.1% vs. 19.9% at 2-year follow-up) [13]. In our
study, 36.8% of ICD recipients for secondary prevention
had recurrent VT/VF, which was comparable to the recur-
rent rate reported in the COMFORT trial.
Ventricular tachyarrhythmia is an important cause of
cardiovascular mortality, morbidity and heart failure
hospitalization in a wide variety of heart diseases [14]. Im-
plantable cardioverter defibrillator is now widely used in
patients who survive sustained VT or VF, or who are at
high risk for sudden cardiac death [1, 15]. Although ICDs
can decrease risk of arrhythmic death, long-term total mor-
tality still depends on the severity of the underlying heart
diseases and associated comorbidities with the increase in
nonarrhythmic deaths completely offsetting the decrease in
arrhythmic deaths [14]. In our study, cardiovascular mortal-
ity was significant higher in the recurrent VT/VF group
than the no recurrence VT/VF group, whereas there was
no difference in the all-cause mortality (including nonar-
rhythmic deaths) between the two groups.
According to current guideline, LV ejection fraction has
been selected as the most important criteria for ICD im-
plantation in primary and secondary prevention settings
[1]. However, several studies have shown improvement of
LV ejection fraction during follow-up in primary prevention
ICD recipients [16, 17]. Notably, Kini et al. reported that
approximately 25% of primary prevention ICD recipients
may no longer meet guideline indications for ICD use at
Fig. 2 Changes in follow-up left ventricular end-diastolic volume
(LVEDV) in the no ventricular tachycardia/ventricular fibrillation (VT/
VF) recurrence group (upper panel) and the recurrent VT/VF group
(lower panel). SD: standard deviation
Table 2 Univariate and multivariate Cox regression analyses in terms of VT/VF recurrence
Univariate analysis Multivariate analysis
Variables Hazard ratio 95% CI p-value Hazard ratio 95% CI p-value
Atrial fibrillation (paroxysmal and persistent) 1.095 0.584 ~ 2.052 0.777
LVEF (%) 0.986 0.970 ~ 1.001 0.074
LVEF ≦ 30% 1.995 1.064 ~ 3.740 0.031
LVEDV (mL) 1.004 1.000 ~ 1.007 0.028
LVEDV > 163.5 mL 2.042 1.170 ~ 3.562 0.012 2.549 1.249 ~ 5.201 0.010
LVESV (mL) 1.004 1.001 ~ 1.008 0.025
Heart failure NYHA functional class ≧ 3 1.293 0.688 ~ 2.430 0.425
QRS width (msec) 1.008 1.000 ~ 1.016 0.059
QRS width > 125 msec 2.067 1.003 ~ 4.260 0.049 2.173 1.030 ~ 4.586 0.042
Ischemic cardiomyopathy 0.998 0.580 ~ 1.717 0.995
Dilated cardiomyopathy 0.851 0.437 ~ 1.655 0.634
Anti-arrhythmic drugs 0.611 0.298 ~ 1.252 0.178
Post VT ablation 0.844 0.272 ~ 2.615 0.768
*Abbreviations: VT ventricular tachycardia, VF ventricular fibrillation, CI confidence interval, LVEF left ventricular ejection fraction, LVEDV left ventricular end diastolic
volume, LVESV left ventricular end systolic volume, NYHA New York Heart Association
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the time of generator replacement due to improvement of
LV ejection fraction, and these ICD recipients received sub-
sequent ICD therapies at a significantly lower rate [16].
Additionally, in MADIT-CRT trial, patients who achieve
LV ejection fraction normalization (>50%) during follow-up
have very low absolute and relative risk of ventricular
tachyarrhythmias and a favorable clinical course within
2.2 years of follow-up, and downgrade from cardiac resyn-
chronization therapy-defibrillator to cardiac resynchroniza-
tion therapy-pacemaker at the time of battery depletion for
cost savings could be considered in these patients if no ven-
tricular tachyarrhythmias have recurred [17]. However, ICD
therapy is reimbursed only for secondary prevention in
many countries, and limited data regarding LV remodeling
as predictor for recurrent VT/VF are available for second-
ary prevention ICD recipients. Klein et al. reported that LV
ejection fraction < 40%, permanent atrial fibrillation and
QRS duration > 150 msec are independent predictors for
VT/VF recurrence in ICD recipients predominantly for sec-
ondary prevention [8]. However, Freedberg et al. reported
that LV ejection fraction was not a predictor for subsequent
ICD therapy in secondary prevention ICD recipients [9]. In
our study for secondary prevention ICD recipients,
LVEDV> 163.5 mL and QRS width > 125 msec were inde-
pendent predictors for recurrence of VT/VF during follow-
up after multivariable adjustment (including LV ejection
fraction, atrial fibrillation and heart failure status), and
LVEF ≤ 30% was no longer a predictor after multivariable
adjustment (Table 2).
Study limitations
There are several limitations in this study. Firstly, this
retrospective analysis bears the inherent limitations of
these types of studies. Secondly, LVEDVs were estimated
by M-mode echocardiography and were corrected by
two-dimensional guided biplanar Simpson’s method of
discs for measurement and this quantified method has
been proven to be an acceptable method to evaluate LV
volume. Moreover, there was a trend that patients with
no recurrent VT/VF were more likely to have reverse re-
modeling of LVEDV during follow-up compared with
patients with recurrent VT/VF (Fig. 2).
Conclusions
LV remodeling and QRS width > 125 msec were independ-
ent predictors for recurrence of VT/VF during follow-up in
secondary prevention ICD recipients under optimal
medical therapy, independent of LV ejection fraction.
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